Day 2 articles

EMBRACE STEMI: Bendavia a new drug to prevent mitochondrial dysfunction in AMI.

The purpose of this phase 2 study was to test the safety and efficacy of new drug bendavia to prevent mitochondrial dysfunction. It was a randomized, double-blind, placebo-controlled study enrolled 58 patients in the bendavia branch and 60 in the control branch. All patients were undergoing anterior ST segment elevation myocardial infarction with TIMI 0/1

NOTION: TAVR in low-risk patients

The aim of this study was to compare the results of transcatheter aortic valve replacement (TAVR) versus surgery in unselected patients with severe degenerative aortic stenosis. Patients were randomized 1:1 to TAVR (n = 145) or surgical replacement (n = 135). Those of TAVR group received Medtronic CoreValve self-expanding valve. The femoral access was used

ODYSSEY LONG TERM: alirocumab reduces LDL in patients with maximum tolerated doses of statins

The aim of this study was to evaluate treatment with alirocumab a monoclonal antibody against PCSK9 receptor, compared with placebo in patients with heterozygous familial hypercholesterolemia or high cardiovascular risk who were at the maximum tolerated dose of statins and LDL >70 mg/dl. A total of 2341 patients randomized to 150 mg alirocumab administered subcutaneously

Top